From: Circulating microRNAs in the early prediction of disease recurrence in primary breast cancer
 | Early (< 3 years) | Late (≥ 5 years) |  | ||
---|---|---|---|---|---|
Characteristic | Number | Percentage | Number | Percentage | P |
Number of patients | 23 | 17 | 20 | 15 | Â |
Age (years) | Â | Â | Â | Â | nsa |
 Median | 55 | 53 |  | ||
 Range | 27–75 | 38–74 |  | ||
Menopausal status | Â | Â | Â | Â | nsa |
 Premenopausal | 8 | 34.8 | 7 | 35 |  |
 Postmenopausal | 15 | 65.2 | 13 | 65 |  |
Tumor size (cm) | Â | Â | Â | Â | nsa |
 T1 | 7 | 30.4 | 8 | 40 |  |
 T2 | 12 | 52.2 | 10 | 50 |  |
 T3 | 4 | 17.4 | 2 | 10 |  |
Histological grade | Â | Â | Â | Â | nsa |
 I | 0 |  | 0 |  |  |
 II | 10 | 43.5 | 6 | 30 |  |
 III | 12 | 52.2 | 14 | 70 |  |
 Lobular | 1 | 4.3 |  |  |  |
Infiltrated lymph nodes | Â | Â | Â | Â | nsa |
 0 | 7 | 30.4 | 3 | 15 |  |
 1–3 | 9 | 39.2 | 6 | 30 |  |
  ≥ 4 | 7 | 30.4 | 11 | 55 |  |
ER |  |  |  |  | < 0.001a |
 Positive | 9 | 39.2 | 19 | 95 |  |
 Negative | 14 | 60.8 | 1 | 5 |  |
PR | Â | Â | Â | Â | 0.006a |
 Positive | 10 | 43.5 | 17 | 85 |  |
 Negative | 13 | 56.5 | 3 | 15 |  |
 Unknown |  |  |  |  |  |
HER2 | Â | Â | Â | Â | nsa |
 Positive | 4 | 17.4 | 4 | 20 |  |
 Negative | 18 | 78.3 | 16 | 80 |  |
 Unknown | 1 | 4.3 |  |  |  |
Adjuvant chemotherapy | Â | Â | Â | Â | nsa |
 Anthracyclines-based | 2 | 8.7 | 2 | 10 |  |
 Taxanes+anthracyclines | 16 | 69.6 | 17 | 85 |  |
 Taxane-based | 5 | 21.7 | 1 | 5 |  |
Hormone therapy | Â | Â | Â | Â | 0.002a |
 Yes | 12 | 52.2 | 19 | 95 |  |
 No | 11 | 47.8 | 1 | 5 |  |